Market accessCompany release

GeneDx Q3 revenue rises to $123.1M but company trims exome and genome growth targets

🇺🇸 GeneDx Holdings Corp. (WGS) · Mon 09 Nov 2026

The US genetic testing company held its full-year revenue guidance at $475-490 million while lowering volume and revenue growth expectations for exome and genome testing.

GeneDx Holdings (Nasdaq: WGS) reported third-quarter 2026 results on 9 November, with revenue of $123.1 million. The company posted adjusted net income of $8.6 million and a GAAP net loss of $12.3 million.

Full-year revenue guidance was left unchanged at $475-490 million. However, GeneDx lowered its targets for exome and genome volume growth and for the related revenue growth.

The company also pointed to developments in reimbursement and sponsored testing. It noted that Medicaid coverage for whole genome sequencing now extends to 25 states. It also announced new sponsored testing programmes with Mirum and Beren.

Only a short summary of the announcement was available for this report, so further detail on the revised guidance figures, the drivers of the change and the terms of the sponsored programmes is not included.

What it means for your team

  • Market-access teams may wish to note that Medicaid coverage for whole genome sequencing is reported in 25 states, a sign of widening public-payer reimbursement for genomic testing.
  • The reduced exome and genome growth targets suggest uptake of these tests may be moving more slowly than the company had previously projected.
  • Sponsored testing programmes with Mirum and Beren show continued industry involvement in supporting genetic diagnosis, relevant to teams working on rare disease pathways.
  • Teams should check the company's full results release for the specific revised guidance numbers before drawing conclusions.

Company's press release (SEC filing): GeneDx Holdings Corp. ↗

Article written by VigiEye from the official source (GeneDx Holdings Corp.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →